Lower back pain, primarily caused by IDD, poses a tremendous societal challenge. Current treatment strategies for IDD fall short in restoring the original function of the intervertebral disc. The research team focused on physiological hypoxia, a characteristic of the nucleus pulposus, due to its unique anatomical configuration.
Researchers at Atrium Health and Wake Forest University School of Medicine have been approved for a $9.9 million research funding award from the Patient-Centered Outcomes Research Institute (PCORI), for a five-year study called “Remote Hypertension Tracking Help and Management to Reduce Disparities in Black Patients (RHYTHM-B).”
Using cells from kidney biopsies, Johns Hopkins Medicine, researchers report progress in the search for more accurate and easier-to-obtain markers to help predict, manage and assess treatment of acute kidney injury (AKI).
Interstitial fluid plays a vital role in drug delivery and tumour treatment. However, few non-invasive measurement methods are available for measuring low-velocity biological fluid flow. Therefore, we developed a novel technology called interstitial flow velocity-MRI. Interstitial flow velocity-MRI has the potential to determine interstitial fluid flow velocity non-invasively and exhibits an intuitive velocity map.
Patients with a history of suicidality experience increased risk in the days surrounding menstruation
Results from mouse models presented at the prestigious American Society of Hematology show that nutrients consumed by an expectant mother during pregnancy can shape their offspring’s blood systems.
Renal dysfunction, especially chronic kidney disease, is the biggest risk factor of mortality among thrombolysed stroke patients, according to a retrospective cohort observational study published in Medicine®, a journal published in the Lippincott portfolio by Wolters Kluwer.
Physician-scientists and other researchers from Sylvester Comprehensive Cancer Center will make presentations at the American Society of Hematology’s 2023 annual meeting Dec. 9-12. This tip sheet highlights several of those presentations.
The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.
By monitoring changes in circulating tumor DNA (ctDNA) among 30 patients treated with immunotherapies for metastatic non-small cell lung cancers, researchers were able to determine molecular response — the clearance of tumor genetic material in the bloodstream.
Baylor Scott & White Heart and Vascular Hospital – Dallas has added an innovative, minimally invasive option for patients with hypertension, or high blood pressure.
Non-Hispanic Black patients with acute myeloid leukemia (AML) are living longer, now that new therapies are available, according to a study presented by researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine’s Abramson Cancer Center at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 955).
In a study led by researchers at Sylvester Comprehensive Cancer Center, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.
New research conducted by investigators at Sylvester Comprehensive Cancer Center and collaborating cancer centers indicates that a new type of targeted therapy may offer new treatment options for patients living with advanced myelofibrosis, a bone marrow disorder. Study results will be shared at ASH 2023 in San Diego, Dec. 9-12.
تقوم أجسامنا كل يوم ببعض الأمور الغريبة وغير المعتادة. فيما يلي بعض الأسئلة والأجوبة التي تقدم التفسير العلمي وراء حدوث ذلك.
The treatment landscape for acute myeloid leukemia (AML) is evolving rapidly, as research discoveries at Sylvester Comprehensive Cancer Center and other academic cancer centers advance new, more effective therapies for this aggressive blood cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
